by Meriem Bouslouk-Marx | 28 Feb 2023
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs. Although I used to represent the G-BA and AMNOG internationally, I did not dare to give a talk solely on orphan drugs. Why? Because I... 
by Meriem Bouslouk-Marx | 14 Feb 2023
The G-BA took the opportunity to announce its AMNOG work programme for 2023 at a press conference on 14 February 2023. The impartial G-BA Chair professor Josef Hecken highlighted in his introduction speech that the G-BA had made over 1,000 benefit assessment decisions... 
by Meriem Bouslouk-Marx | 10 Feb 2023
While the last day of February is known as the Rare Disease Day, the first days of February 2023 mark the start of changes for rare diseases at the G-BA in Germany. So let us explore why February is a special month for orphan drugs at the G-BA! On 2 February 2023, the... 
by Meriem Bouslouk-Marx | 6 Dec 2022
Why does this year’s World Orphan Drug Congress in the province of Barcelona still feel so special? I DID NOT represent my former employer, the Federal Joint Committee (G-BA) in Germany. I DID NOT present any update on the G-BA benefit assessment of orphan drugs under... 
by Meriem Bouslouk-Marx | 18 Jul 2022
In the current draft of the Act on the Stabilisation of Finances for the Statutory Health Insurance in Germany, the threshold for orphan drugs shall decrease from currently €50 to €20m. A déjà vu? But wasn’t it €30m last time this was mentioned? Would €25m be a... 
by Meriem Bouslouk-Marx | 1 Jun 2022
Back on stage! This year’s RAPS Euro Convergence in Amsterdam gave Dr. Meriem Bouslouk-Marx the floor to outline the interdependencies of EU and national legislative reviews. She analysed the implications of potential changes of the EU Orphan legislation such as...